Product Information
TRIAMTERENE-HYDROCHLOROTHIAZIDE 75-50 MG TAB is a generic product labeled by Actavis Pharma, Inc., priced at $0.1312 per EA under NDC 00591034801. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Nov 30, 1988. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
50; 75 mg/1; mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00591034801
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
HYDROCHLOROTHIAZIDE; TRIAMTERENEApproval Type
Generic (ANDA)
FDA Application
ANDA071851FDA Approved
11/30/1988
TE Code
AB
On Market Since
9/23/1993
Pharmacological Classes
Price Statistics
The NADAC for TRIAMTERENE-HYDROCHLOROTHIAZIDE 75-50 MG TAB has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 29.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1312 per EA |
|---|---|
| All-time high | $0.2159 (Feb 12, 2014) |
| All-time low | $0.0859 (Nov 20, 2024) |
| 52-week high | $0.1312 |
| 52-week low | $0.1115 |
| Median price | $0.1315 |
| Average price | $0.1370 |
| Largest weekly change | +26.7% (Jul 20, 2016) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 9% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Triamterene and Hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Potassium-sparing Diuretic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRIAMTERENE-HYDROCHLOROTHIAZIDE 75-50 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for TRIAMTERENE-HYDROCHLOROTHIAZIDE 75-50 MG TAB, manufactured by Actavis Pharma, Inc., is $0.1312 per EA (NDC 00591034801), effective Sep 30, 2026.
How has the price of TRIAMTERENE-HYDROCHLOROTHIAZIDE 75-50 MG TAB changed over time?
Over the history we have for it, the NADAC for TRIAMTERENE-HYDROCHLOROTHIAZIDE 75-50 MG TAB has declined 29.8%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TRIAMTERENE-HYDROCHLOROTHIAZIDE 75-50 MG TAB?
Since Nov 28, 2013, the NADAC for TRIAMTERENE-HYDROCHLOROTHIAZIDE 75-50 MG TAB has ranged from a low of $0.0859 (Nov 20, 2024) to a high of $0.2159 (Feb 12, 2014), with a median of $0.1315 per EA.
Are there cheaper alternatives to TRIAMTERENE-HYDROCHLOROTHIAZIDE 75-50 MG TAB?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TRIAMTERENE-HYDROCHLOROTHIAZIDE 75-50 MG TAB, is $0.1199 per EA — about 9% below TRIAMTERENE-HYDROCHLOROTHIAZIDE 75-50 MG TAB.
Who manufactures TRIAMTERENE-HYDROCHLOROTHIAZIDE 75-50 MG TAB?
TRIAMTERENE-HYDROCHLOROTHIAZIDE 75-50 MG TAB (NDC 00591034801) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.